Key Takeaways
- Boston Scientific shares tumbled approximately 10% following management’s announcement of reduced full-year organic growth projections to 6.5%–8% during the Bernstein Strategic Decisions Conference.
- Second-quarter organic growth expectations were downgraded to 5%–7%, significantly below previous forecasts.
- The WATCHMAN procedure segment experienced its first volume decline since February, alongside softness in electrophysiology and Urology divisions.
- Shares touched a 52-week low of $50.75 during trading, representing a nearly 46% decline year-over-year.
- Despite the selloff, numerous Wall Street firms maintain positive ratings, with price objectives spanning $60 to $90.
Shares of Boston Scientific Corp (BSX) plummeted approximately 10% during morning hours on May 27 following an unexpected guidance revision delivered by CEO Mike Mahoney and Chief Medical Officer Dr. Janar Sathananthan at Bernstein’s 42nd Annual Strategic Decisions Conference.
Boston Scientific Corporation, BSX
The medical device manufacturer’s shares declined to an intraday bottom of $50.75, establishing a fresh 52-week low, before mounting a modest recovery. During afternoon trading, BSX exchanged hands near $52.79, representing a decline of approximately 10%.
The conference presentation—a 50-minute question-and-answer format beginning around 8:00 a.m. Eastern Time—caught investors off guard with its unexpected guidance adjustment. Management unveiled revised full-year organic growth projections of 6.5%–8%, while establishing second-quarter organic growth expectations at merely 5%–7%. Both figures fell considerably short of market anticipations.
The organization attributed the downturn to challenges across three critical business segments: electrophysiology (EP), WATCHMAN, and Urology. Notably, WATCHMAN procedure volumes experienced their inaugural decline beginning in February—a development that particularly concerned investors closely monitoring this division.
Executives acknowledged robust demand for concomitant WATCHMAN procedures while highlighting a substantial deceleration in standalone cases. Hospital capacity limitations and reimbursement modifications were cited as contributing factors.
Wall Street Reaction
The revised guidance intensified an already challenging period for analyst perspectives on BSX.
Daiwa had previously downgraded the stock to Neutral from Outperform, reducing its price objective to $60 from $83. BofA trimmed its target to $68 from $105, while maintaining a Buy recommendation.
However, not all analysts are retreating. Truist Securities reaffirmed a Buy rating with an $85 price target following a separate $1.5 billion equity commitment in MiRus. TD Cowen maintained its Buy stance with an $80 objective. Piper Sandler preserved its Overweight rating alongside a $90 target.
The substantial spread in price targets—ranging from $60 to $90—reflects significant uncertainty surrounding the stock’s trajectory.
Pressures Facing the Company
Beyond the guidance reduction, management highlighted tariff-related margin compression as an additional challenge. Competitive market share losses in the EP segment also emerged as a concern.
BSX had already experienced pressure throughout the previous month as growth apprehensions intensified regarding the EP and WATCHMAN divisions. Today’s conference commentary simply quantified what market participants had been anticipating.
The broader equity markets provided little support. The S&P 500 and Nasdaq closed essentially unchanged, while the Dow Jones posted only marginal gains. BSX’s decline was company-specific.
During last month’s earnings conference call, CEO Mahoney characterized the environment as “unanticipated headwinds and changing business patterns.” He employed identical language at the Bernstein event.
InvestingPro analysis currently indicates BSX trades below its Fair Value calculation. The company’s PEG ratio stands at 0.32, a metric that frequently suggests opportunity for growth-focused investors.
Additionally, the organization maintains a $5 billion share repurchase authorization, with $3 billion remaining available—and recently executed a $2 billion accelerated share repurchase arrangement.
BSX’s FRACTURE pivotal study for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter achieved its primary safety and effectiveness objectives, enrolling 420 participants throughout the United States and Europe.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
